TY  - JOUR 
AU  - Guinea, Jesus
AU  - Pelaez, Teresa
AU  - Recio, Sandra
AU  - Torres-Narbona, Marta
AU  - Bouza, Emilio
PY  - 2008
SN  - 0066-4804
UR  - http://hdl.handle.net/20.500.12020/1249
AB  - Isavuconazole (BAL4815) is a promising novel broad-spectrum triazole in late-stage clinical development
that has proven active in vitro against Aspergillus and Candida species. We compared the in vitro activities of this agent with those of...
LA  - en
PB  - American Society for Microbiology
TI  - In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species
DO  - 10.1128/AAC.01512-07
T2  - Antimicrobial Agents and Chemotherapy
M2  - 1396
KW  - Cell-transplant recipients
KW  - Amphotericin B
KW  - Triazole BAL4815
KW  - Dose pharmacokinetics
KW  - Healthy-volunteers
KW  - Active component
KW  - Itraconazole
KW  - BAL8557
KW  - Prodrug
KW  - Susceptibility
VL  - 52
ER  -